Erratum: Nitric oxide synthase mediates the ability of darbepoetin alfa to improve the cognitive performance of STOP null mice (Neuropsychopharmacology (2010) doi:10.1038/npp.2010.36);Nitric oxide synthase mediates the ability of darbepoetin alfa to improve the cognitive performance of STOP null mice

Neuropsychopharmacology

Volumn 35, Issue 8, 2010, Pages 1718-1728

  Kajitani, Kosuke ^a   Thorne, Michael ^a   Samson, Michel ^a   Robertson, George S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Darbepoetin alfa; L NAME; Nitric oxide; Novel objective recognition task; Schizophrenia; STOP null mouse

Indexed keywords

MICROTUBULE ASSOCIATED PROTEIN; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; STABLE TUBULE ONLY POLYPEPTIDE; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; LEARNING; MALE; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOGNITION;

EID: 77953609944     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.66     Document Type: Erratum

References (74)

1. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F et al (2008). Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6: 37.
2. Adembri C, Bechi A, Meli E, Gramigni E, Venturi L, Moroni F et al (2004). Erythropoietin attenuates post-traumatic injury in organotypic hippocampal slices. J Neurotrauma 21: 1103-1112.
3. Akbarian S, Bunney Jr WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA et al (1993a). Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50: 169-177.
4. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney Jr WE, Jones EG (1993b). Distorted distribution of nicotinamide-adenine dinu-cleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50: 178-187.
5. Andreasen NC, Flaum M (1991). Schizophrenia: the characteristic symptoms. Schizophr Bull 17: 27-49.
6. Andrieux A, Salin PA, Vernet M, Kujala P, Baratier J, Gory-Faure S et al (2002). The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev 16: 2350-2364.
7. Arancio O, Kiebler M, Lee CJ, Lev-Ram V, Tsien RY, Kandel ER et al (1996). Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell 87: 1025-1035.
8. Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, Krasnova IN et al Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry. (originally published online Jan. 5, 2010, at www.nature.com/mp/journal/vaop/ ncurrent/abs/mp2009144a.html).
9. Begou M, Volle J, Bertrand JB, Brun P, Job D, Schweitzer A et al (2008). The stop null mice model for schizophrenia displays [corrected] cognitive and social deficits partly alleviated by neuroleptics. Neuroscience 157: 29-39.
10. Boehning D, Snyder SH (2003). Novel neural modulators. Annu Rev Neurosci 26: 105-131.
11. Bosc C, Andrieux A, Job D (2003). STOP proteins. Biochemistry 42: 12125-12132.
12. Bouvrais-Veret C, Weiss S, Hanoun N, Andrieux A, Schweitzer A, Job D et al (2008). Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neuro-transmission. J Neurochem 104: 745-756.
13. Breier A (2005). Developing drugs for cognitive impairment in schizophrenia. Schizophr Bull 31: 816-822.
14. Brenner E, Sonnewald U, Schweitzer A, Andrieux A, Nehlig A (2007). Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia. J Neurosci Res 85: 3487-3493.
15. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al (2000). Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526-10531.
16. Broadbent NJ, Squire LR, Clark RE (2004). Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci USA 101: 14515-14520.
17. Brun P, Begou M, Andrieux A, Mouly-Badina L, Clerget M, Schweitzer A et al (2005). Dopaminergic transmission in STOP null mice. J Neurochem 94: 63-73.
18. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR et al (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 102: 8627-8632.
19. Carlsson A, Waters N, Waters S, Carlsson ML (2000). Network interactions in schizophreniaFtherapeutic implications. Brain Res Brain Res Rev 31: 342-349.
20. Cherian L, Goodman JC, Robertson C (2007). Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 322: 789-794.
21. Dawson TM, Snyder SH (1994). Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 14: 5147-5159.
22. Delotterie D, Ruiz G, Brocard J, Schweitzer A, Roucard C, Roche Y et al (2010). Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology (Berlin) 208: 131-141.
23. Denarier E, Aguezzoul M, Jolly C, Vourc'h C, Roure A, Andrieux A et al (1998). Genomic structure and chromosomal mapping of the mouse STOP gene (Mtap6). Biochem Biophys Res Commun 243: 791-796.
24. Eastwood SL, Lyon L, George L, Andrieux A, Job D, Harrison PJ (2007). Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol 21: 635-644.
25. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M et al (2004). Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 9: 42-54.
26. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S et al (2007). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12: 206-220.
27. El-Kordi A, Radyushkin K, Ehrenreich H (2009). Erythropoietin improves operant conditioning and stability of cognitive performance in mice. BMC Biol 7: 37.
28. Feil R, Kleppisch T (2008). NO/cGMP-dependent modulation of synaptic transmission. Handb Exp Pharmacol 184: 529-560.
29. Fradley RL, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS (2005). STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163: 257-264.
30. Furchgott RF, Vanhoutte PM (1989). Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007-2018.
31. Galiano MR, Bosc C, Schweitzer A, Andrieux A, Job D, Hallak ME (2004). Astrocytes and oligodendrocytes express different STOP protein isoforms. J Neurosci Res 78: 329-337.
32. Ghezzi P, Brines M (2004). Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11(Suppl 1): S37-S44.
33. Harrison PJ (1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122(Part 4): 593-624.
34. Hope BT, Michael GJ, Knigge KM, Vincent SR (1991). Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci USA 88: 2811-2814.
35. Hope BT, Vincent SR (1989). Histochemical characterization of neuronal NADPH-diaphorase. J Histochem Cytochem 37: 653-661.
36. Hori SE, Powell KJ, Robertson GS (2007). Darbepoetin alfa (Aranesp) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults. Neuroscience 144: 1-7.
37. Jablensky A (2004). Resolving schizophrenia's CATCH22. Nat Genet 36: 674-675.
38. Keefe RS, Fenton WS (2007). How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 33: 912-920.
39. Kendrick KM, Guevara-Guzman R, Zorrilla J, Hinton MR, Broad KD, Mimmack M et al (1997). Formation of olfactory memories mediated by nitric oxide. Nature 388: 670-674.
40. Kiss JP, Vizi ES (2001). Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci 24: 211-215.
41. Lee BH, Kim YK (2008). Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res 104: 36-43.
42. Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P (2004). Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 56: 767-777.
43. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000). Molecular characterization of schizophrenia viewed by micro-array analysis of gene expression in prefrontal cortex. Neuron 28: 53-67.
44. Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ (2008a). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res 184: 313-321.
45. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, Harmer CJ (2008b). Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology 33: 611-618.
46. Miskowiak K, O'Sullivan U, Harmer CJ (2007). Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 27: 2788-2792.
47. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ et al (2009). Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology (Berlin) 207: 133-142.
48. Moncada S, Palmer RM, Higgs EA (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
49. Mueser KT, McGurk SR (2004). Schizophrenia. Lancet 363: 2063-2072.
50. Orhan B, Yalcin S, Nurlu G, Zeybek D, Muftuoglu S (2004). Erythropoietin against cisplatin-induced peripheral neurotoxi-city in rats. Med Oncol 21: 197-203.
51. Ota KT, Pierre VJ, Ploski JE, Queen K, Schafe GE (2008). The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase. Learn Mem 15: 792-805.
52. Powell KJ, Hori SE, Leslie R, Andrieux A, Schellinck H, Thorne M et al (2007). Cognitive impairments in the STOP null mouse model of schizophrenia. Behav Neurosci 121: 826-835.
53. Prast H, Philippu A (1992). Nitric oxide releases acetylcholine in the basal forebrain. Eur J Pharmacol 216: 139-140.
54. Prast H, Philippu A (2001). Nitric oxide as modulator of neuronal function. Prog Neurobiol 64: 51-68.
55. Ranganath C, Minzenberg MJ, Ragland JD (2008). The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry 64: 18-25.
56. Robertson GS, Hori SE, Powell KJ (2006). Schizophrenia: an integrative approach to modelling a complex disorder. J Psychiatry Neurosci 31: 157-167.
57. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K et al (2000). Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice over-expressing erythropoietin. Proc Natl Acad Sci USA 97: 11609-11613.
58. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S et al (1998). Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253: 26-32.
59. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635-4640.
60. Sawa A, Snyder SH (2002). Schizophrenia: diverse approaches to a complex disease. Science 296: 692-695.
61. Schuman EM, Madison DV (1991). A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 254: 1503-1506.
62. Shimizu H, Iwayama Y, Yamada K, Toyota T, Minabe Y, Nakamura K et al (2006). Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr Res 84: 244-252.
63. Singbartl G (1994). Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 72(6 Suppl): S36-S43.
64. Son H, Hawkins RD, Martin K, Kiebler M, Huang PL, Fishman MC et al (1996). Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell 87: 1015-1023.
65. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC et al (2001). Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berlin) 158: 140-145.
66. Tanaka K, Yagi T, Shimakoshi R, Azuma K, Nanba T, Ogo H et al (2009). Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice. Neurosci Lett 462: 235-238.
67. van Os J, Kapur S (2009). Schizophrenia. Lancet 374: 635-645.
68. Vincent SR, Kimura H (1992). Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 46: 755-784.
69. Wang HG, Lu FM, Jin I, Udo H, Kandel ER, de Vente J et al (2005). Presynaptic and postsynaptic roles of NO, cGK, and RhoA in long-lasting potentiation and aggregation of synaptic proteins. Neuron 45: 389-403.
70. Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ (2004). Double dissociation between the effects of peripostrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci 24: 5901-5908.
71. Yamamoto M, Koshimura K, Sohmiya M, Murakami Y, Kato Y (2004). Effect of erythropoietin on nitric oxide production in the rat hippocampus using in vivo brain microdialysis. Neuroscience 128: 163-168.
72. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A et al (2003). Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029.
73. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122: 150-202.
74. Zhang W, Sun B, Wang X, Liu J, Zhang Z, Geng S (2010). Erythropoietin enhances survival of facial motor neurons by inhibiting expression of inducible nitric oxide synthase after axotomy. J Clin Neurosci 17: 368-371.